Date: 2015-09-18
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the joint Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Congress of Chemotherapy and Infection (ICC) 2015 meeting
Company: AmpliPhi BioSciences (USA - VA)
Product: bacteriophage cocktail against Staphylococcus aureus
Action
mechanism: bacteriophage
Disease:
Therapeutic area: Infectious diseases
Country:
Trial details:
Latest
news: * On September 18, 2015, AmpliPhi Biosciences announced experimental results highlighting that its prototype bacteriophage cocktail demonstrated comparable efficacy to vancomycin in reduction of Staphylococcus aureus (S. aureus) in a murine lung infection model. Data from this study, performed in collaboration with the Hearts Consulting Group and the University of North Texas (UNT) Health Science Center, were presented at the joint Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Congress of Chemotherapy and Infection (ICC) 2015 meeting, taking place in San Diego from September 17-21. To assess the in vivo efficacy of bacteriophages to treat lung infections, neutropenic immunocompromised (ICR) mice were inoculated intranasally with S. aureus. At two hours post infection, scaled dosing of the bacteriophage cocktail was administered intranasally to three dosage groups (50 µl; n=5 for each group), with a second identical dose administered at six hours post infection. Vancomycin was administered subcutaneously at two and six hours post infection to a fourth, positive control group. Two control groups were infected, but untreated. The groups treated with the bacteriophage cocktail at the two highest doses (1 x 109 and 1 x 108 PFU per phage per dose) showed a 3-log reduction in bacterial cell counts relative to untreated controls at the same time point, which was comparable to the efficacy seen in the positive control group treated with vancomycin. Poster : Efficacy of a Bacteriophage Cocktail in a Staphylococcus aureus Mouse Pneumonia Model is Comparable to Vancomycin)
